Perceptive Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Perceptive Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,643	Closed	-$1.05M	–	121
2019 Q4	$1.05M	Hold	3,643	–	–	0.02%	94
2019 Q3	$526K	Buy	+3,643	New	+$494K	0.01%	98
2014 Q3	–	Sell	-3,043	Closed	-$2.13M	–	135
2014 Q2	$2.13M	Buy	+3,043	New	+$1.42M	0.21%	63

Other funds holding KPTI

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Perceptive Advisors's KPTI Position: Q1 2020 in Review

Perceptive Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2020, closing a stake of 3,643 shares — an estimated $1.05M sold.

Perceptive Advisors first reported a position in KPTI in Q2 2014 and held it in 3 quarters. The position peaked at $2.13M in Q2 2014. 136 funds tracked by Wall St. Rank hold KPTI as of Q1 2020.

Perceptive Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2020 after selling out during the quarter.
Perceptive Advisors sold 3,643 Karyopharm Therapeutics shares in Q1 2020, an estimated $1.05M.
Perceptive Advisors first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 3 quarters.
Perceptive Advisors's Karyopharm Therapeutics position peaked at $2.13M in Q2 2014.
136 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2020.

Based on Perceptive Advisors's 13F filing for Q1 2020, filed 15 May 2020.